Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.

Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD.

Kloeckener-Gruissem B, Barthelmes D, Labs S, Schindler C, Kurz-Levin M, Michels S, Fleischhauer J, Berger W, Sutter F, Menghini M.

Invest Ophthalmol Vis Sci. 2011 Jul 1;52(7):4694-702. doi: 10.1167/iovs.10-6080.

PMID:
21282580
2.

Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.

Smailhodzic D, Muether PS, Chen J, Kwestro A, Zhang AY, Omar A, Van de Ven JP, Keunen JE, Kirchhof B, Hoyng CB, Klevering BJ, Koenekoop RK, Fauser S, den Hollander AI.

Ophthalmology. 2012 Nov;119(11):2304-11. doi: 10.1016/j.ophtha.2012.05.040. Epub 2012 Jul 26.

PMID:
22840423
3.

CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.

McKibbin M, Ali M, Bansal S, Baxter PD, West K, Williams G, Cassidy F, Inglehearn CF.

Br J Ophthalmol. 2012 Feb;96(2):208-12. doi: 10.1136/bjo.2010.193680. Epub 2011 May 10.

PMID:
21558292
4.

Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.

Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A.

Ophthalmology. 2007 Dec;114(12):2168-73.

PMID:
18054635
5.
6.

Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.

Yamashiro K, Tomita K, Tsujikawa A, Nakata I, Akagi-Kurashige Y, Miyake M, Ooto S, Tamura H, Yoshimura N.

Am J Ophthalmol. 2012 Jul;154(1):125-36. doi: 10.1016/j.ajo.2012.01.010. Epub 2012 Apr 1.

PMID:
22465368
7.

Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.

Abedi F, Wickremasinghe S, Richardson AJ, Islam AF, Guymer RH, Baird PN.

Ophthalmology. 2013 Aug;120(8):1641-8. doi: 10.1016/j.ophtha.2013.01.014. Epub 2013 Apr 9.

PMID:
23582991
8.

Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy.

Jirarattanasopa P, Ooto S, Nakata I, Tsujikawa A, Yamashiro K, Oishi A, Yoshimura N.

Invest Ophthalmol Vis Sci. 2012 Jun 14;53(7):3663-72. doi: 10.1167/iovs.12-9619.

PMID:
22570352
9.
10.

Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.

Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.

Ophthalmology. 2009 Dec;116(12):2393-9. doi: 10.1016/j.ophtha.2009.05.039. Epub 2009 Oct 7.

PMID:
19815292
11.

Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration.

Nischler C, Oberkofler H, Ortner C, Paikl D, Riha W, Lang N, Patsch W, Egger SF.

Acta Ophthalmol. 2011 Jun;89(4):e344-9. doi: 10.1111/j.1755-3768.2010.02080.x. Epub 2011 Jan 14.

12.

Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.

Orlin A, Hadley D, Chang W, Ho AC, Brown G, Kaiser RS, Regillo CD, Godshalk AN, Lier A, Kaderli B, Stambolian D.

Retina. 2012 Jan;32(1):4-9. doi: 10.1097/IAE.0b013e31822a2c7c.

PMID:
21878851
13.

Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.

Hermann MM, van Asten F, Muether PS, Smailhodzic D, Lichtner P, Hoyng CB, Kirchhof B, Grefkes C, den Hollander AI, Fauser S.

Ophthalmology. 2014 Apr;121(4):905-10. doi: 10.1016/j.ophtha.2013.10.047. Epub 2013 Dec 21.

PMID:
24365177
14.

Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.

Abedi F, Wickremasinghe S, Richardson AJ, Makalic E, Schmidt DF, Sandhu SS, Baird PN, Guymer RH.

Ophthalmology. 2013 Jan;120(1):115-21. doi: 10.1016/j.ophtha.2012.10.006. Epub 2012 Nov 11.

PMID:
23149126
15.

Genetic association with response to intravitreal ranibizumab for neovascular age-related macular degeneration in the Han Chinese population.

Yuan D, Yuan D, Liu X, Yuan S, Xie P, Liu Q.

Ophthalmologica. 2013;230(4):227-32. doi: 10.1159/000355068. Epub 2013 Sep 25.

PMID:
24080590
16.

Phenotype and genotype characteristics of age-related macular degeneration in a Japanese population.

Mori K, Horie-Inoue K, Gehlbach PL, Takita H, Kabasawa S, Kawasaki I, Ohkubo T, Kurihara S, Iizuka H, Miyashita Y, Katayama S, Awata T, Yoneya S, Inoue S.

Ophthalmology. 2010 May;117(5):928-38. doi: 10.1016/j.ophtha.2009.10.001. Epub 2010 Feb 4.

PMID:
20132989
17.
18.

Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).

Hagstrom SA, Ying GS, Pauer GJT, Sturgill-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF; Comparison of AMD Treatments Trials Research Group.

Ophthalmology. 2013 Mar;120(3):593-599. doi: 10.1016/j.ophtha.2012.11.037. Epub 2013 Jan 18.

19.

Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population.

Kang HK, Yoon MH, Lee DH, Chin HS.

Korean J Ophthalmol. 2012 Dec;26(6):414-22. doi: 10.3341/kjo.2012.26.6.414. Epub 2012 Nov 12.

20.

Supplemental Content

Support Center